SCHEMBL7673383

SCHEMBL7673383

Cc1c(C(=O)N/N=C\c2ccc(OC(F)F)cc2)[nH]c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
LMNA P02545 3/20 0.56
THRB P10828 2/20 0.56
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
KDM4E B2RXH2 4/20 0.53
POLB P06746 3/20 0.53
TP53 P04637 1/20 0.51
ALDH1A1 P00352 5/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 5/20 0.49
HPGD P15428 1/20 0.48
HTT P42858 2/20 0.46
FAAH O00519 1/20 0.46
MITF O75030 1/20 0.46
PKM P14618 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7531906 1.00 MAPT (0.56) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7561469 0.88 MAPT (0.53) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7561480 0.88 MAPT (0.53) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7561630 0.87 MAPT (0.67) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7561632 0.87 MAPT (0.67) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7527554 0.86 MAPT (0.61) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7677946 0.86 MAPT (0.61) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7561130 0.85 MEN1 (0.62) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7561135 0.85 MEN1 (0.62) MAPTSMN1; SMN2LMNATHRBMEN1
SCHEMBL7557764 0.84 MAPT (0.74) MAPTSMN1; SMN2LMNATHRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885SMN1; SMN2 4745/4885LMNA 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.